US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 1.15 against a street estimate of 0.97 — a beat of 18.6%.
Analysts rate Indivior PLC Ordinary Shares a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $49.00.
| Fund | Stake |
|---|---|
| BlackRock Inc | 15.85% |
| Vanguard Portfolio Management, LLC | 6.42% |
| Oaktree Capital Management LLC | 5.19% |
| Vanguard Capital Management, LLC | 4.66% |
| State Street Corp | 4.23% |
| Two Seas Capital LP | 4.02% |
| Fuller & Thaler Asset Management Inc | 3.91% |
| Morgan Stanley - Brokerage Accounts | 2.88% |
| Document | Date |
|---|---|
| Shareholder vote results · Q4 2026 HEADLINE NUMBERS • Indivior held a special stockholder meeting on October 15, 2026, regarding the proposed merger. • The company’s stockholders appr | 2026-10-15 |
| Company announcement · Q4 2026 MERGER UPDATE • Indivior and Supernus plan to combine under an August 1, 2026 merger agreement. • Indivior will be renamed Supernus, Inc., with Supe | 2026-10-06 |
| Reg FD disclosure · Q3 2026 INDIVIOR PHARMACEUTICALS, INC. – FORM 8-K SUMMARY Filed September 17, 2026 --- HEADLINE NUMBERS • Special cash dividend declared: $8.13 per share o | 2026-09-17 |
| Current report · Q3 2026 INDIVIOR PHARMACEUTICALS, INC. – FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Indivior manufactures and supplies SUBOXONE® Tablets and SUBUTEX® | 2026-09-15 |
| Quarterly report · Q2 2026 INDIVIOR PHARMACEUTICALS, INC. - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Net revenue Q2 2026: $343 million (vs. $302 million Q2 2025; +13.6% increas | 2026-08-03 |
| Reg FD disclosure · Q3 2026 INDIVIOR PHARMACEUTICALS 8-K SUMMARY HEADLINE NUMBERS • Filing Date: August 3, 2026 • Company: Indivior Pharmaceuticals, Inc. (Ticker: INDV, Nasdaq) | 2026-08-03 |
| Results announced · Q3 2026 INDIVIOR PHARMACEUTICALS Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Total net revenue Q2 2026: $343 million, up 14% year-over-year (vs. $302 millio | 2026-08-03 |
| Material agreement · Q3 2026 INDIVIOR PHARMACEUTICALS, INC. — FORM 8-K SUMMARY HEADLINE NUMBERS • Merger Agreement signed August 1, 2026 between Indivior Pharmaceuticals, Inc. a | 2026-08-03 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $8.13 / share ex-date Oct 30, 2026 · pay Nov 6, 2026 | 2026-10-30 |
| Announcement | Date |
|---|---|
| Special cash dividend declared contingent on Supernus merger closing Indivior Pharmaceuticals announced a special cash dividend of $8.13 per share, contingent on closing its merger with Supernus Pharmaceuticals expected around November 2, 2026. The dividend w | 2026-09-17 |
| Entered into merger agreement with Supernus Pharmaceuticals Indivior Pharmaceuticals announced on August 1, 2026 that it has agreed to merge with Supernus Pharmaceuticals in an all-stock transaction. Under the merger agreement, each Supernus share wi | 2026-08-03 |
| Agreement and Plan of Merger executed with Supernus Pharmaceuticals Indivior Pharmaceuticals announced on August 3, 2026, that it has signed a merger agreement to acquire Supernus Pharmaceuticals. The companies executed the Agreement and Plan of Merger dated | 2026-08-03 |
| Accelerated share repurchase agreement for $175 million announced Indivior Pharmaceuticals announced on May 4, 2026, that it entered into an accelerated share repurchase (ASR) agreement with an investment bank to buy back $175 million of its own stock. Thi | 2026-05-04 |
| Financial guidance for 2026 announced with updated corporate presentation Indivior PLC, a pharmaceutical company trading on NASDAQ under ticker INDV, filed an 8-K on January 8, 2026 to disclose the issuance of a press release and updated corporate presentation ann | 2026-01-08 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Indivior PLC Ordinary Shares — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.